COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Rizatriptan 10 MG RPD in the Treatment of Acute Migraine (Rinotama)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01057160
Recruitment Status : Completed
First Posted : January 27, 2010
Last Update Posted : January 28, 2013
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Hans-Christoph Diener, Universität Duisburg-Essen

Brief Summary:
This is a multicentre, open label, prospective, randomized, two-attack study with active comparator in patients reporting inadequate response to analgesics and/or triptans to examine the efficacy of Rizatriptan 10 mg RPD in this group of patients.

Condition or disease Intervention/treatment Phase
Migraine Drug: Rizatriptan Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 195 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study of the Efficacy and Safety of Rizatriptan 10 mg RPD in the Treatment of Acute Migraine in Patients With Non Satisfactory Response to Previous Pharmacologic Treatment
Study Start Date : May 2008
Actual Primary Completion Date : June 2010
Actual Study Completion Date : June 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Migraine
Drug Information available for: Rizatriptan

Arm Intervention/treatment
Experimental: intake of rizatriptan 10 mg Drug: Rizatriptan
use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic

Active Comparator: previous used analgesic Drug: Rizatriptan
use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic

Primary Outcome Measures :
  1. Percentage of patients with headache response on a one to four scale after 2 hours. [ Time Frame: 2 hours ]

Secondary Outcome Measures :
  1. Percentage of patients being headache free two hours after intake of study medication. Time of dosing to onset of headache relieve. Relief of concomitant symptoms. Rate of sustained pain free Percentage of patients needing rescue medication [ Time Frame: (time points 0.5, 1, 1.5, 2, 4, 8, 12, 24 hours after drug intake ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient's signature on the informed consent document [each patient should be given ample time to read (or have read to them) the consent form, ask any questions they may have regarding the trial and have a clear understanding of the trial and the procedures involved prior to the signing of the consent form].
  • Have a clinical diagnosis of migraine with or without aura according to IHS criteria at least one year prior to enrollment.
  • At screening at least two migraine attacks per month and no more than ten during the last three months prior to inclusion.
  • At screening a stable dose of prophylactic medication (including no prophylactic treatment) for at least two months and no change of prophylactic medication during active trial period.

Exclusion Criteria:

  • Contraindication to triptans or Rizatriptan according to medical information sheet.
  • Patient has a history or clinical evidence of ischemic heart disease (e.g., angina pectoris of any type, history of myocardial infarction or documented silent ischemia) or symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm (including Prinzmetal's variant angina), or other significant underlying cardiovascular disease. Patient has uncontrolled hypertension. Patient has either demonstrated hypersensitivity to or experienced a serious adverse event in response to Rizatriptan or any of its inactive ingredients.
  • History of treatment failure for at least one triptan for the treatment of acute migraine attacks.
  • Any other headache, except tension type headache on 5 or less days a month within three months prior to screening.
  • A history of drug induced headache, medication overuse headache or any other addiction.
  • Any history of allergic hypersensitivity or poor tolerance to any components of the preparations used in this trial.
  • Females of childbearing potential not using reliable means of birth control, pregnant or lactating females or expected/ planned pregnancy.
  • Participation (planned or current) in any investigational drug or device trial within the previous 30 days prior to screening visit.
  • Inability to understand the trial procedures, and thus inability to give informed consent.
  • History of allergy to sulfa drugs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01057160

Layout table for location information
Department of Neurology, University Hospital Essen
Essen, Germany, 45147
Sponsors and Collaborators
Universität Duisburg-Essen
Merck Sharp & Dohme Corp.
Layout table for investigator information
Principal Investigator: Hans-Christoph Diener, Prof. Department of Neurology, University Essen
Layout table for additonal information
Responsible Party: Hans-Christoph Diener, Prof. of Neurology, Universität Duisburg-Essen Identifier: NCT01057160    
Other Study ID Numbers: MK 462
First Posted: January 27, 2010    Key Record Dates
Last Update Posted: January 28, 2013
Last Verified: January 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs